June 8, 2020 / 3:43 PM / 24 days ago

BRIEF-EMA Gets Application For CMA Of Remdesivir

June 8 (Reuters) - Gilead Sciences Inc:

* EMA RECEIVES APPLICATION FOR CONDITIONAL AUTHORISATION OF FIRST COVID-19 TREATMENT IN THE EU

* EMA - RECEIVED APPLICATION FOR CMA OF ANTIVIRAL MEDICINE REMDESIVIR FOR THE TREATMENT OF COVID-19 AND FORMALLY STARTED ITS EVALUATION

* EMA - ASSESSMENT OF THE BENEFITS AND RISKS OF REMDESIVIR IS BEING PERFORMED UNDER A REDUCED TIMELINE

* EMA - ASSESSMENT OF BENEFITS AND RISKS OF REMDESIVIR BEING PERFORMED UNDER REDUCED TIMELINE AND OPINION COULD BE ISSUED WITHIN WEEKS

* EMA - IF REMDESIVIR BENEFITS OUTWEIGH RISKS IN COVID-19 TREATMENT, EMA TO LIAISE WITH EUROPEAN COMMISSION TO SUPPORT FAST-TRACKING OF DECISION-MAKING

* EMA - IF REMDESIVIR BENEFITS OUTWEIGH RISKS IN TREATMENT, EMA TO LIAISE FOR GRANTING OF MARKETING AUTHORISATION BY EUROPEAN COMMISSION VALID IN ALL EU1AND EEA MEMBER STATES Source text for Eikon: [ID:here ] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below